Rochelle Hanley, M.D., F.A.C.P., served as the Chief Medical Officer of Viking Therapeutics, Inc. from April 2013 until her retirement in September 2016. Dr. Hanley has a strong background in drug development, specifically focusing on diabetes and metabolic disorders, with...

Rochelle Hanley, M.D., F.A.C.P., served as the Chief Medical Officer of Viking Therapeutics, Inc. from April 2013 until her retirement in September 2016. Dr. Hanley has a strong background in drug development, specifically focusing on diabetes and metabolic disorders, with over 20 years of experience in the field. She has worked with notable companies like GlaxoSmithKline and Quatrx Pharmaceuticals, where she was responsible for significant clinical programs. At Viking, she was in charge of driving the company's clinical trial strategies and objectives but left the role due to completing predefined milestones rather than any disagreement with the company. In her final year at Viking in 2016, her total compensation was around $133,751, but there were no bonuses as corporate performance objectives were not met that year. Interestingly, during her tenure, she had substantial stock option awards that did not vest due to her resignation. Dr. Hanley's deep expertise is backed by an impressive academic record, which includes numerous awards and recognitions in the medical community.